Answers are grounded in this paper and cite their sources.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive, immune-mediated syndrome of the peripheral nerves characterized by proximal and distal motor and sensory symptoms. Diagnostic delays and misdiagnosis are common with CIDP, and it is associated with significant disease and treatment burden. Evolving science has identified biomarkers driving diagnostic and treatment innovation in CIDP, warranting guidance for payers. To discuss managed care considerations in CIDP, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in May 2026. This article provides a qualitative summary of the panel discussion along with key insights and suggested payer practices meant to support informed coverage decisions and guide future work such as collaboration, research, and advocacy. Two key insights identified were that diagnostic challenges and current treatment limitations are primary unmet needs in the care of patients with CIDP and payer management is focused on supporting timely, appropriate treatment to mitigate disease progression and increased health care resource utilization. Additionally, participants see potential value in emerging biomarkers and treatments with new mechanisms of action. Suggested payer practices include providing care management or other resources, aligning coverage criteria with clinical practice, and evolving CIDP management strategy based on advancing science.
No takes yet. Share an insight, caveat, or question.
Flavin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: